ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole
| dc.contributor.author | Avery, Lisa M. | |
| dc.contributor.author | Steed, Molly E. | |
| dc.contributor.author | Woodruff, Ashley E. | |
| dc.contributor.author | Hasan, Muhammad | |
| dc.contributor.author | Rybak, Michael J. | |
| dc.date.accessioned | 2015-05-05T20:59:28Z | |
| dc.date.available | 2015-05-05T20:59:28Z | |
| dc.date.issued | 2012-11 | |
| dc.identifier.citation | Avery et. al. "Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole." Antimicrob. Agents Chemother. November 2012 vol. 56 no. 11 5990-5993 http://dx.doi.org/10.1128/AAC.01046-12 | en_US |
| dc.identifier.uri | http://hdl.handle.net/1808/17607 | |
| dc.description.abstract | We report two cases of daptomycin (DAP)-nonsusceptible (DNS) vancomycin-intermediate Staphylococcus aureus (VISA) vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Both patients responded rapidly and favorably to this combination. The clinical isolates from the two patients were tested post hoc in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model to confirm the bactericidal activity and enhancement of daptomycin and trimethoprim-sulfamethoxazole. The combination of high-dose daptomycin and trimethoprim-sulfamethoxazole should be explored further for the treatment of DNS VISA strains. | en_US |
| dc.description.sponsorship | M.J.R. has received grant support, consulted for, or provided lectures for Astellas, Cubist, Forest, Clinical Therapeutics, Theravance, and Rib- X. L.M.A has served as an advisory board member (Forest) and provided lectures (Astellas) and owns stock (Merck). M.E.S., A.E.W., and M.H. have no potential conflicts of interest. | en_US |
| dc.publisher | American Society for Microbiology | en_US |
| dc.title | Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole | en_US |
| dc.type | Article | |
| kusw.kuauthor | Steed, Molly E. | |
| kusw.kudepartment | Department of Pharmaceutical Chemistry | en_US |
| dc.identifier.doi | 10.1128/AAC.01046-12 | |
| kusw.oaversion | Scholarly/refereed, publisher version | |
| kusw.oapolicy | This item meets KU Open Access policy criteria. | |
| dc.rights.accessrights | openAccess |
